Insider filing report for Changes in Beneficial Ownership
- Schedule 13G & 13D forms are used to report a party's ownership of stock which exceeds 5% of a company's total stock issue.
- Schedule 13G is a shorter version of Schedule 13D with fewer reporting requirements.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. 1)*
VERVE THERAPEUTICS INC
(Name of Issuer)
COMMON STOCK
(Title of Class of Securities)
92539P101
(CUSIP Number)
DECEMBER 31, 2022
(Date of Event Which Requires Filing of This Statement)
Check the appropriate box to designate the rule pursuant to
which this Schedule is filed:
[ ] Rule 13d-1(b)
[X] Rule 13d-1(c)
[ ] Rule 13d-1(d)
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities,
and for any subsequent amendment containing information which would alter
the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be
deemed to be "filed" for the purpose of Section 18 of the Securities Exchange
Act of 1934 ("Act") or otherwise subject to the liabilities of that section of
the Act but shall be subject to all other provisions of the Act (however,
see the Notes).
CUSIP No. 92539P101
1 NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS
(ENTITIES ONLY):
James R. Singer
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)
(a) [ ]
(b) [ ]
3 SEC USE ONLY
4 CITIZENSHIP OR PLACE OF ORGANIZATION United States of America
NUMBER OF 5 SOLE VOTING POWER 5,000,000
SHARES
BENEFICIALLY 6 SHARED VOTING POWER None
OWNED BY
EACH REPORTING 7 SOLE DISPOSITIVE POWER 5,000,000
PERSON WITH:
8 SHARED DISPOSITIVE POWER None
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
5,000,000
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN
SHARES (see instructions)
[ ]
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
8.1%
12 TYPE OF REPORTING PERSON (see instructions)
IN
Item 1(a). Name of Issuer:
VERVE THERAPEUTICS INC
Item 1(b). Address of Issuer's Principal Executive Offices:
500 Technology Square, Suite 901
Cambridge, MA 02139
US
Item 2(a). Name of Person Filing:
The person filing this report is James R. Singer.
Item 2(b). Address of Principal Business Office or, if none, Residence:
PO Box 1395, Yarmouth, ME 04096
Item 2(c). Citizenship:
United States of America
Item 2(d). Title of Class of Securities:
Common Stock
Item 2(e). CUSIP Number: 92539P101
Item 3. Statements filed pursuant to rules 13D-1(b) or 13D-2(B) or (C)
Not applicable
Item 4. Ownership.
The information set forth in Rows 5 through 9 and 11 of the cover pages
of this Schedule 13G is incorporated herein by reference.
Item 5. Ownership of Five Percent or Less of a Class.
Not applicable.
Item 6. Ownership of More Than Five Percent on Behalf of Another Person.
Not applicable.
Item 7. Identification and Classification of the Subsidiary Which Acquired the
Security Being Reported on by the Parent Holding Company.
Not applicable.
Item 8. Certification.
By signing below I certify that, to the best of my knowledge and belief,
the securities referred to above were not acquired and are not held
for the purpose of or with the effect of changing or influencing the
control of the issuer of the securities and were not acquired and are
not held in connection with or as a participant in any transaction
having such purpose or effect, other than activities solely in connection
with a nomination under 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify
that the information set forth in this statement is true, complete and correct.
February 1, 2023
Date
/S/James R. Singer
Signature
JAMES R. SINGER
Name/Title